Legend Biotech CORP 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

11 Mar 2025

LEGN

Legend Biotech CORP

20-F: Legend Biotech Reports Full Year 2024 Financial Results, Citing Strong CARVYKTI Sales

Legend Biotech's 20-F filing highlights significant revenue growth driven by CARVYKTI sales, alongside ongoing investments in research and development.

NASDAQ

19 Mar 2024

LEGN

Legend Biotech CORP

20-F: Legend Biotech Details Securities Registration in 20-F Filing

Legend Biotech's 20-F filing details the registration of its American depositary shares (ADS) and ordinary shares on the Nasdaq Global Select Market as of December 31, 2023, along with comprehensive information on share structure, shareholder rights, and corporate governance.